211914-51-1

• 常用中文名：达比加群
• 常用英文名：Dabigatran (BIBR 953)
• CAS号：211914-51-1
• 分子式：C₂₅H₂₅N₇O₃
• 分子量：471.511
• 相关类别： 原料药 血液系统用药 抗凝血药及抗血小板药
• 发布时间：2018-02-08 08:00:00
• 更新时间：2026-07-02 17:04:16
• Dabigatran(BIB-953; BIBR 953ZW)是可逆的高活性直接凝血酶抑制剂(DTI),Ki为4.5 nM。

名称

• 中文名: 达比加群
• 英文名: dabigatran
• 中文别名: 达比加群-13C6; 达比加群杂质108; 达比加群脂杂质B; 甲磺酸达比加群杂质; 达比加群杂质21; N-[[2-[[[4-(氨咪甲基)苯基]氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]-N-2-吡啶基-Β-丙氨酸; 达比加群脂; DTI抑制剂(DABIGATRAN); 达比加群,G,5万; 达比加群酯杂质A; 达比加群酯杂质A对照品; 达必佳群; DABIGATRAN (BIBR 953),达比加群; 达比加群酯DABIGATRANETEXILATEMESILATE; 达比加群,G; 氘4-达比加群盐酸盐; 达比加群标准品; N-[[2-[[[4-(氨基亚氨基甲基)苯基]氨基]甲基]-1-甲基-1H-苯并[D]咪唑-5-基]羰基]-N-吡啶-2-基-BETA-丙氨酸; N-[[2-[[[4-(氨咪甲基)苯基]氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]-N-2-吡啶基-β-丙氨酸; 达比加群检测标准品; 达比加群酯杂质; 3-[1-甲基-2-[[(4-甲脒基苯基)氨基]甲基]-N-(2-吡啶基)苯并咪唑-5-甲酰氨基]丙酸; 达比加群杂质; 达比加群杂质C; 达比加群杂质B; 达比加群(THROMBIN抑制剂); 罗恩 达比加群 R024541; 达比加群酯杂质A123; 原研代码BIBR0953
• 英文别名: BIB-953; 3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid; Dabigatran in acetonitrile; 3-[[2-[(4-cbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid Dabigatran; UNII-I0VM4M70GC; Dabigatran //BP; b-Alanine,N-[[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl; Dabigtan -IP/BP/HIS; Dabigatran API; Dabigatran; BIBR-953; N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-beta-alanine; 3-[2-[[(4-Cbamimidoylphenyl)amino]methyl]-1-methyl-N-(2-pyridyl)benzimidazole-5-cboxamido]propanoic Acid; Dabiga oup; BIBR953;BIBR 953;BIBR-953; Dabigatran etexilate impurity189; BIBR 953(Dabigatran); Dabigatran etexilate-1; Dabigatran3-(2-((4-cbamimidoylphenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-cboxamido)propanoic acid; N- (2-{ (4-cbaMiMidoylphenyl)amino Methyl}-1-Met; N-[[2-[[[4-(AMinoiMinoMethyl)phenyl]amino]Methyl]-1-Methyl-1H-benzo[d]iMidazol-5-yl]carbonyl]-N-pyridin-2-yl-beta-alanine; 3-[[2-[(4-cbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid; 3-(2-((4-cbamimidoylphenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-cboxamido)propanoic acid; BIBR 953ZW; 3-[[2-[[(4-cbaMiMidoylphenyl)amino]Methyl]-1-Met; Dabigatran(BIB-953; 3-[[2-[[(4-cbamimidoylphenyl)amino]methyl]-1-methyl-benzoimidazole-5-carbonyl]-pyridin-2-yl-amino]propanoic acid; Dabigatran Etexilate Mesilate; ethyl 3-(2-(((4-(N'-((hexan-2-yloxy)carbonyl)cbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-cboxamido)propanoate; Dabigatran Standd; Dabigatran Impurity b; Dabigatran etexilate impurity1513; Dabigatran Impurity U; Dabigatran (Acid); N-[(2-{[(4-cbaMiMidoylphenyl)amino]Methyl}-1-Methyl-1HbenziMidazol- 5-yl)carbonyl]-N-pyridin-2-yl-beta-alanine; BIBR 953 (Dabigatran, Pradaxa); 3-[[2-[(4-cbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic; BIBR 953;BIBR 953ZW;BIBR953;BIB-953; 3-[[2-[[(4-cbaMiMidoylphenyl)amino]Methyl]-1-Methyl-benzoiMidazole-5-carbonyl]-pyridin-2-yl-amino]; Dabigatran base; Desethyl Dabigatran Etexilate Impurity D; Dabigatran Ester Impurity B; β-Alanine,N-[[2-[[[4-(aMinoiMinoMethyl)phenyl]amino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]carbonyl]-N-2-pyridinyl; DabigatranQ: What is Dabigatran Q: What is the CAS Number of Dabigatran Q: What is the storage condition of Dabigatran Q: What e the applications of Dabigatran; Dabigatran AKSci B955; D4-Dabigatran hydrochloride; N-[(2-{[(4-cbamimidoylphenyl)amino]methyl}-1-methyl-1H-ben

物化性质

• 密度: 1.4±0.1 g/cm3
• 沸点: 797.1±70.0 °C at 760 mmHg
• 熔点: 268-272ºC
• 分子式: C₂₅H₂₅N₇O₃
• 分子量: 471.511
• 闪点: 435.9±35.7 °C
• 精确质量: 471.201874
• PSA: 150.22000
• LogP: 0.79
• 外观性状: 黄褐色固体
• 蒸汽压: 0.0±2.9 mmHg at 25°C
• 折射率: 1.694
• 储存条件: Refrigerator, Under Inert Atmosphere

生物活性

• 描述: Dabigatran(BIB-953; BIBR 953ZW)是可逆的高活性直接凝血酶抑制剂(DTI),Ki为4.5 nM。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> 凝血酶
  研究领域 >> 心血管疾病
• 参考文献:

  [1]. Wienen W, Stassen JM, Priepke H, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally activeprodrug, dabigatran etexilate. Thromb Haemost. 2007 Jul;98(1):155-62.

  [2]. Kansal AR, Sorensen SV, Gani R, Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients withatrial fibrillation. Heart. 2012 Apr;98(7):573-8.